GLP-1 treatment was not statistically significantly different compared to control at reducing the risk of developing dry AMD at one and three years after treatment, but GLP-1 receptor agonists did lower dry AMD risk at five and 10 years after treatment by 9.2% and 14.9%, respectively
They are not on your side
Maybe people who cant manage their weight feel depressed about that and maybe people who start a GLP-1 and lose weight have a positive sense of self efficacy and that makes them feel good
Amazon One Medical kiosks have been stocking Novo Nordisks Wegovy pills since January
Here are some stats: Pancreatitis is seen in about 0.2% of people in studies, which is similar to people not taking the drug, but its still a known risk so its taken seriously
GLP-1 receptor agonist 8 has the potential for the research of diabetes, obesity, and nonalcoholic fatty liver disease (NAFLD) (extracted from patent WO2019239319A1, compound 17) [1]